What is NSRX's health score?

Nasus Pharma Ltd (NSRX) has a TradeApes health score of 44 out of 100, rated Weak. This composite score evaluates financial strength, operating trends, valuation, capital allocation, and risk factors.

What is NSRX's estimated fair value?

Based on our 5-year discounted cash flow model, Nasus Pharma Ltd's estimated fair value is $N/A per share. This is a model estimate, not a price target or investment recommendation.

Is NSRX undervalued or overvalued?

Our model currently rates NSRX as Inconclusive. This assessment combines health metrics, valuation multiples, and market sentiment. Individual investors should conduct their own due diligence.

To Unlock Full Report

2 free score cards remaining

Nasus Pharma Ltd (NSRX)

Healthcare Inconclusive inconclusive weak

$3.08

Updated: 2026-07-14

TradeApes Score

Financial Strength

50 Mixed

Operating Trend

30 Weak

Relative Value

50 Mixed

Capital Allocation

35 Weak

Risk Management

65 Healthy

Key Findings

+ Strong liquidity — current assets more than 2× current liabilities

Unlock Full Report →

− Significant dilution — share count up more than 5% year over year

Unlock Full Report →

Industry Related Stocks

ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) Aardvark Therapeutics, Inc. (AARD) Abivax S.A. (AAVXF) Ascend Wellness Holdings, Inc. (AAWH) AbbVie Inc. (ABBV) AbCellera Biologics Inc. (ABCL)

See all Healthcare stocks →

TradeApes provides financial data, analytics, and research tools. TradeApes is not a registered investment adviser, broker-dealer, or tax advisor. The information presented is for educational and informational purposes only and does not constitute investment, financial, or tax advice.

11 sector-leading stocks delivered to your inbox every Sunday. Free.

No spam. Unsubscribe anytime.